ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gilead Sciences has licensed three small-molecule antiviral programs from Novartis. Gilead will pay an undisclosed sum and up to $291 million in future milestones for Novartis’s herpes virus, influenza, and rhinovirus programs. Separately, Gilead will pay Durect $25 million to license a long-lasting injectable antiviral for HIV. Durect could earn $145 million more in milestone payments, and Gilead has the option to license additional Durect antiviral programs for HIV and hepatitis B.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X